IPM 014B
Status:Completed
Phase:II, I
Principal Investigator(s):Dr Annalene Nel
Objective:The purpose of this study is to determine whether dapivirine gel 4789 is safe for daily use by healthy women in South Africa.
Prevention Option(s):Microbicides
Study Design:Randomized
Arms and Assigned Interventions
Descriptiondosage: 1.25mg dapivirine/day
frequency: once daily
duration: 6 weeks
Mode of DeliveryGel
ARMsExperimental
Official Code:
NCT00917904
Start Date
End Date
July 1, 2009
September 1, 2009
Enrollment:100
Age range:
18 Years ↔
40 Years
Population:Cisgender Women